Skip to main content
. Author manuscript; available in PMC: 2010 Jul 1.
Published in final edited form as: Atherosclerosis. 2008 Dec 24;205(1):325–330. doi: 10.1016/j.atherosclerosis.2008.12.020

Figure 2.

Figure 2

Changes in plasma HDL-C, apo A-I, and HDL subpopulations in the placebo (upper panel), estrogen (middle panel), and estrogen + progestin (lower panel) arms of the ERA trial. HDL subpopulations are expressed as mg/dL of plasma apo A-I. * P<0.001, relative to changes in the placebo arm. Data expressed as mean change±SE.